临床和实验医学杂志
臨床和實驗醫學雜誌
림상화실험의학잡지
JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
2015年
16期
1364-1367
,共4页
郭东来%李鹏%韩振魁%斯坎德尔·努尔买买提
郭東來%李鵬%韓振魁%斯坎德爾·努爾買買提
곽동래%리붕%한진괴%사감덕이·노이매매제
结肠癌%COLO205 细胞%增殖%塞来昔布%COX-2%MMP-9
結腸癌%COLO205 細胞%增殖%塞來昔佈%COX-2%MMP-9
결장암%COLO205 세포%증식%새래석포%COX-2%MMP-9
Human colon carcinoma%COLO205%Proliferation%Celecoxib%COX - 2%MMP - 9
目的:研究塞来昔布在体外对人结肠癌细胞 COLO205生长增殖及对环氧化酶2(COX -2)、金属蛋白酶9(MMP -9)mRNA 表达的影响。方法体外培养人结肠癌细胞 COLO205,分组为正常对照组和塞来昔布干预组,MTT 法检测正常对照组和塞来昔布组抑制率,塞来昔布在不同时间且相同浓度的条件下,不同时间对于结肠癌细胞增殖的影响,测得抑制率并算得半抑制浓度(IC50)值;RT - PCR 检测 COX -2、MMP -9的 mRNA 的表达影响。结果 MTT 结果显示:相同浓度的塞来昔布干预结肠癌 COLO205细胞,分别在24 h,48 h,72 h 测算 IC50结果为:96.620±9.044μmol/ L、71.561±5.706μmol/ L、58.982±11.069μmol/ L,塞来昔布浓度提高和干预时间延长,结肠癌 COLO205细胞活力下降。RT - PCR 结果显示:正常对照组与塞来昔布干预组 COX -2 mRNA 灰度值分别为:0.832±0.012,0.113±0.001,干预组塞来昔布干预细胞的 COX -2mRNA 表达降低,所应显示的条带消失,无表达率,两组比较差异有显著性( t =18.051,P =0.000);正常对照组与塞来昔布干预组 MMP -9 mRNA 灰度值分别为:0.756±0.050,0.171±0.001,干预组 MMP -9 mRNA 表达明显降低,条带消失,无 mRNA 表达,两组比较差异有显著性( t =17.286,P =0.001)。结论体外实验表明:塞来昔布抑制结肠癌 COLO205细胞增殖,通过抑制 COX -2及 MMP -9的 mRNA 的表达来实现抗肿瘤作用。
目的:研究塞來昔佈在體外對人結腸癌細胞 COLO205生長增殖及對環氧化酶2(COX -2)、金屬蛋白酶9(MMP -9)mRNA 錶達的影響。方法體外培養人結腸癌細胞 COLO205,分組為正常對照組和塞來昔佈榦預組,MTT 法檢測正常對照組和塞來昔佈組抑製率,塞來昔佈在不同時間且相同濃度的條件下,不同時間對于結腸癌細胞增殖的影響,測得抑製率併算得半抑製濃度(IC50)值;RT - PCR 檢測 COX -2、MMP -9的 mRNA 的錶達影響。結果 MTT 結果顯示:相同濃度的塞來昔佈榦預結腸癌 COLO205細胞,分彆在24 h,48 h,72 h 測算 IC50結果為:96.620±9.044μmol/ L、71.561±5.706μmol/ L、58.982±11.069μmol/ L,塞來昔佈濃度提高和榦預時間延長,結腸癌 COLO205細胞活力下降。RT - PCR 結果顯示:正常對照組與塞來昔佈榦預組 COX -2 mRNA 灰度值分彆為:0.832±0.012,0.113±0.001,榦預組塞來昔佈榦預細胞的 COX -2mRNA 錶達降低,所應顯示的條帶消失,無錶達率,兩組比較差異有顯著性( t =18.051,P =0.000);正常對照組與塞來昔佈榦預組 MMP -9 mRNA 灰度值分彆為:0.756±0.050,0.171±0.001,榦預組 MMP -9 mRNA 錶達明顯降低,條帶消失,無 mRNA 錶達,兩組比較差異有顯著性( t =17.286,P =0.001)。結論體外實驗錶明:塞來昔佈抑製結腸癌 COLO205細胞增殖,通過抑製 COX -2及 MMP -9的 mRNA 的錶達來實現抗腫瘤作用。
목적:연구새래석포재체외대인결장암세포 COLO205생장증식급대배양화매2(COX -2)、금속단백매9(MMP -9)mRNA 표체적영향。방법체외배양인결장암세포 COLO205,분조위정상대조조화새래석포간예조,MTT 법검측정상대조조화새래석포조억제솔,새래석포재불동시간차상동농도적조건하,불동시간대우결장암세포증식적영향,측득억제솔병산득반억제농도(IC50)치;RT - PCR 검측 COX -2、MMP -9적 mRNA 적표체영향。결과 MTT 결과현시:상동농도적새래석포간예결장암 COLO205세포,분별재24 h,48 h,72 h 측산 IC50결과위:96.620±9.044μmol/ L、71.561±5.706μmol/ L、58.982±11.069μmol/ L,새래석포농도제고화간예시간연장,결장암 COLO205세포활력하강。RT - PCR 결과현시:정상대조조여새래석포간예조 COX -2 mRNA 회도치분별위:0.832±0.012,0.113±0.001,간예조새래석포간예세포적 COX -2mRNA 표체강저,소응현시적조대소실,무표체솔,량조비교차이유현저성( t =18.051,P =0.000);정상대조조여새래석포간예조 MMP -9 mRNA 회도치분별위:0.756±0.050,0.171±0.001,간예조 MMP -9 mRNA 표체명현강저,조대소실,무 mRNA 표체,량조비교차이유현저성( t =17.286,P =0.001)。결론체외실험표명:새래석포억제결장암 COLO205세포증식,통과억제 COX -2급 MMP -9적 mRNA 적표체래실현항종류작용。
Objective To study celecoxib in vitro human colon cancer cell growth and proliferation of COLO205 and its anti - tumor molecu-lar mechanisms. Methods Cultured human colon cancer COLO205,MTT method analyses celecoxib at the same concentration,at different times for the colon cancer cell were used to calculate IC50 value. RT - PCR method was used to evaluate the expression of COX -2,MMP -9 mRNA. Results MTT assay showed:the concentration of the same intervention celecoxib to inhibit the proliferation of human colon cancer cells,its 24 h,48 h,72 h IC50 of respectively:96. 620 ±9. 044 μmol/ L,71. 561 ± 5. 706 μmol/ L,58. 982 ± 11. 069 μmol/ L. The RT - PCR results show:human colon cancer cells COLO205 in normal control group and celecoxib in the intervention group,respectively. The COX -2mRNA gray value were:0. 832 ± 0. 012,0. 113 ±0. 001( t =18. 051,P =0. 000). MMP - 9 mRNA gray values were:0. 801 ± 0. 022,0. 102 ± 0. 001( t = 19. 037,P = 0. 000);MMP -9 mRNA were 0. 756 ±0. 050,0. 171 ±0. 001( t =17. 286,P = 0. 001). Conclusion Celecoxib inhibition of gastric cancer cell prolifera-tion,celecoxib antitumor mechanisms may by inhibiting the expression of COX -2 and MMP -9 mRNA in implementation.